This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Our mission is to change lives by changing the course of blood cancer January 2025 Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the Company's belief that RYTELO is a highly differentiated treatment with blockbuster potent ...

For Geron Corporation (GERN) , 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia in June.  Geron’s shares have risen 61.1% in the past year against a decrease of 15.6% for the industry. Here we discuss some reasons for the same. Image Source: Zacks Investment ResearchGERN’s Rytelo Enjoys Strong Demand TrendsThe approval of Rytelo gave Geron ...

Performance and Growth - Geron (NASDAQ: GERN) has significantly outperformed expectations in the first full quarter of launch, with substantial investor interest driving financial inflows [1] - The company's performance metrics show remarkable growth percentages, including 1212%, 1200%, and 1000%, indicating a strong upward trajectory [2][4] Investor Tools and Resources - The Total Pharma Tracker service provides a comprehensive set of tools for DIY investors, including a software feature that allows users to enter any ticker and access extensive curated research material [2][3] - In-house experts offer hands-on support by utilizing these tools to identify the best investible stocks, complete with buy/sell strategies and alerts [3] Historical Performance - Historical data from 2017 to 2023 shows a cumulative performance with notable fluctuations, including a -6% in 2018 and a -19% in 2022, but overall positive growth trends [2][4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) DELAWARE 75-2287752 (State or other jurisdi ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .It has been a year and a half since my last look at an oncology name called Geron Corporation (NASDAQ: GERN ) . To understate things, it has been a busy and potentially transformat ...

Geron Corporation (NASDAQ:GERN) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chairman and CEO Jim Ziegler - EVP and CCO Michelle Robertson - EVP and CFO Faye Feller - EVP, CMO Andrew Grethlein - EVP, COO Conference Call Participants Tara Bancroft - T. D. Cowen Faisal Khurshid - Leerink Partners Corinne Johnson - Goldman Sachs Carter Gould - Barclays Emily Bodnar - H.C. Wainwright Stephen Will ...

Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.56%. A quarter ago, it was expected that this drugmaker would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Over the last four quarters, the company has surpassed consens ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $ ...

Exhibit 99.1 geror Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt FOSTER CITY, Calif., November 7, 2024 -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aimi ...